INSILICO issues positive profit warning, forecasting a swing to USD33.50–39.50 million H1 2026 profit on revenue surge to over USD100 million

Bulletin Express

Jul 09

InSilico Medicine Cayman TopCo (INSILICO) expects a sharp turnaround for the six months ended 30 June 2026, according to a positive profit warning released on 9 July.

Revenue is projected at USD102.50–106.50 million, a jump of approximately 272.70%–287.30% from USD27.50 million a year earlier.

The company anticipates net profit of USD33.50–39.50 million, reversing the USD19.20 million net loss booked in the first half of 2025.

Adjusted non-IFRS net profit is estimated at USD45.50–51.50 million, versus an adjusted non-IFRS loss of USD15.40 million a year ago.

Management attributes the improvement to substantial growth in out-licensing, co-development and research collaboration income, alongside enhanced operating efficiency.

Figures are based on unaudited management accounts. INSILICO plans to release its full interim results in August 2026 and advises shareholders and potential investors to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1159081504"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159081504\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159081504?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 08:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159081504","market":"us","top_or_hot":-1,"title":"INSILICO issues positive profit warning, forecasting a swing to USD33.50–39.50 million H1 2026 profit on revenue surge to over USD100 million","media":"Bulletin Express","content":"<p>InSilico Medicine Cayman TopCo (INSILICO) expects a sharp turnaround for the six months ended 30 June 2026, according to a positive profit warning released on 9 July.</p>\n<p>Revenue is projected at USD102.50–106.50 million, a jump of approximately 272.70%–287.30% from USD27.50 million a year earlier.</p>\n<p>The company anticipates net profit of USD33.50–39.50 million, reversing the USD19.20 million net loss booked in the first half of 2025.</p>\n<p>Adjusted non-IFRS net profit is estimated at USD45.50–51.50 million, versus an adjusted non-IFRS loss of USD15.40 million a year ago.</p>\n<p>Management attributes the improvement to substantial growth in out-licensing, co-development and research collaboration income, alongside enhanced operating efficiency.</p>\n<p>Figures are based on unaudited management accounts. INSILICO plans to release its full interim results in August 2026 and advises shareholders and potential investors to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INSILICO issues positive profit warning, forecasting a swing to USD33.50–39.50 million H1 2026 profit on revenue surge to over USD100 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINSILICO issues positive profit warning, forecasting a swing to USD33.50–39.50 million H1 2026 profit on revenue surge to over USD100 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-09 08:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>InSilico Medicine Cayman TopCo (INSILICO) expects a sharp turnaround for the six months ended 30 June 2026, according to a positive profit warning released on 9 July.</p>\n<p>Revenue is projected at USD102.50–106.50 million, a jump of approximately 272.70%–287.30% from USD27.50 million a year earlier.</p>\n<p>The company anticipates net profit of USD33.50–39.50 million, reversing the USD19.20 million net loss booked in the first half of 2025.</p>\n<p>Adjusted non-IFRS net profit is estimated at USD45.50–51.50 million, versus an adjusted non-IFRS loss of USD15.40 million a year ago.</p>\n<p>Management attributes the improvement to substantial growth in out-licensing, co-development and research collaboration income, alongside enhanced operating efficiency.</p>\n<p>Figures are based on unaudited management accounts. INSILICO plans to release its full interim results in August 2026 and advises shareholders and potential investors to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1159081504","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159081504","pubTimestamp":1783556558,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"InSilico Medicine Cayman TopCo (INSILICO) expects a sharp turnaround for the six months ended 30 June 2026, according to a positive profit warning released on 9 July. Revenue is projected at...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"INSILICO发布正面盈利预警，预计随着收入飙升至1亿美元以上，2026年上半年利润将增至33.50-3950万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"InSilico Medicine Cayman TopCo (INSILICO) expects a sharp turnaround for the six months ended 30 June 2026, according to a positive profit warning released on 9 July.\nRevenue is projected at USD102.50–106.50 million, a jump of approximately 272.70%–287.30% from USD27.50 million a year earlier.\nThe company anticipates net profit of USD33.50–39.50 million, reversing the USD19.20 million net loss booked in the first half of 2025.\nAdjusted non-IFRS net profit is estimated at USD45.50–51.50 million, versus an adjusted non-IFRS loss of USD15.40 million a year ago.\nManagement attributes the improvement to substantial growth in out-licensing, co-development and research collaboration income, alongside enhanced operating efficiency.\nFigures are based on unaudited management accounts. INSILICO plans to release its full interim results in August 2026 and advises shareholders and potential investors to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}